Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH₂Mab-250 in Human Breast Cancer Xenografts.

ABSTRACT: Monoclonal antibody (mAb) and cell-based immunotherapies represent cutting-edge strategies for cancer treatment. However, safety concerns persist due to the potential targeting of normal cells that express reactive antigens. Therefore, it is crucial to develop cancer-specific mAbs (CasMabs) that can bind to cancer-specific antigens and exhibit antitumor activity in vivo, thereby reducing the risk of adverse effects. We previously screened mAbs targeting human epidermal growth factor receptor 2 (HER2) and successfully developed a cancer-specific anti-HER2 mAb, H₂Mab-250/H₂CasMab-2 (mouse IgG₁, kappa). In this study, we assessed both the in vitro and in vivo antitumor efficacy of the humanized H₂Mab-250 (humH₂Mab-250). Although humH

SUBMITTER: Kaneko MK 

PROVIDER: S-EPMC11817376 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature